Department of Orthopedics, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Department of Cardiology, The First Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Pain Pract. 2018 Jun;18(5):597-610. doi: 10.1111/papr.12649. Epub 2017 Nov 28.
This study aims to evaluate the efficacy and safety of parecoxib injection in pain relief after laparoscopic surgeries.
A comprehensive literature search based on 4 online databases (PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science) was applied to retrieve all related randomized controlled trials (RCTs). Two independent reviewers screened each article for eligibility according to the predetermined inclusion criteria. The Cochrane Collaboration's tool was applied to evaluate the methodological quality of included studies. A standardized data collection sheet was designed to extract data from included studies. RevMan version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) was selected to perform meta-analysis.
A total of 1,060 participants who were scheduled for gynecological laparoscopic surgery or laparoscopic cholecystectomy (LC) were enrolled in 12 selected RCTs. The methodological qualities of the studies were evaluated as moderate to high. The combined data showed that perioperative parecoxib injection could significantly reduce the proportion of patients who required adjuvant pain relieve after laparoscopic surgeries. Significantly lower pain scores in the parecoxib groups were observed, which proved that preoperative or intraoperative injection of 40 mg parecoxib was more effective than placebo for immediate pain relief after LC. But preoperative injection of 40 mg parecoxib showed no improvement compared with placebo in the management of immediate pain following gynecological laparoscopic surgery. The occurrence of adverse events showed no differences between perioperative parecoxib administration and placebo control.
Perioperative parecoxib administration was effective in reducing the proportion of patients who required adjuvant pain relief after laparoscopic surgeries without significant adverse events compared with placebo. The effect of parecoxib injection on immediate pain relief remains in question. Future RCTs with larger sample sizes are encouraged.
本研究旨在评估帕瑞昔布注射用于腹腔镜手术后疼痛缓解的疗效和安全性。
通过 4 个在线数据库(PubMed、Embase、Cochrane 中央对照试验注册库和 Web of Science)进行全面文献检索,以检索所有相关的随机对照试验(RCT)。两名独立的审查员根据预先确定的纳入标准筛选每个文章的合格性。采用 Cochrane 协作工具评估纳入研究的方法学质量。设计了一个标准化的数据采集表,从纳入的研究中提取数据。采用 RevMan 版本 5.3(Cochrane 协作,哥本哈根,丹麦)进行荟萃分析。
共有 1060 名计划接受妇科腹腔镜手术或腹腔镜胆囊切除术(LC)的患者纳入了 12 项选定的 RCT。研究的方法学质量被评估为中等至较高。综合数据表明,围手术期帕瑞昔布注射可显著降低腹腔镜手术后需要辅助止痛的患者比例。帕瑞昔布组的疼痛评分明显较低,这表明术前或术中注射 40 mg 帕瑞昔布在 LC 后即刻止痛方面比安慰剂更有效。但是,术前注射 40 mg 帕瑞昔布在管理妇科腹腔镜手术后即刻疼痛方面与安慰剂相比没有改善。围手术期帕瑞昔布给药与安慰剂对照组的不良反应发生率无差异。
与安慰剂相比,围手术期帕瑞昔布给药可有效降低腹腔镜手术后需要辅助止痛的患者比例,且无明显不良反应。帕瑞昔布注射对即刻疼痛缓解的效果仍存在疑问。鼓励进行更大样本量的未来 RCT。